Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 1
---
 promotes the development and commercialization of a risk diversified portfolio to address
unmet medical needs with resilience and efficiency.

1

Our corporate organization and ownership of subsidiaries is illustrated
by the following chart*:

Portfolio Overview

OSR’s subsidiaries (other than RMC) have diverse scientific and
technological developments, and are engaged in distinct areas of therapeutics research and development, including oral T-cell immunotherapies
and recombinant biologics. This approach not only provides the Company with a broader scope of potential therapeutic solutions but also
reduces the risks associated with a singular-asset approach.

Figure 2 below summarizes our three subsidiaries, two of which have
their own drug development pipelines.

    Portfolio Company
     
    Science, Technology and Platform

    T-cell immunotherapies based on a live attenuated, safe, orally, available bacterial vaccine strain, genetically modified to develop and elicit patients’ cytotoxic T-cells against specific pre-defined targets

    Platform integrating different protein domain sequences linking into a Design augmented recombinant biologic with enhanced biological functionality

    Neurovascular surgical devices

Figure 2. the Company portfolio
company snapshot.

2

Intellectual Property Overview

We own or have in-licensed numerous patents and intellectual property
underlying patent applications and possess substantial know-how and trade secrets relating to the development and commercialization
of therapeutic product candidates in development by our portfolio companies, including related manufacturing processes and technologies.
As of December 31, 2024, the patent portfolio of our subsidiaries includes 10 patent families of issued patents and pending patent
applications in various stages of prosecution. Generally, the patents issued and patent applications pending are in multiple jurisdictions
including the United States, Europe, Japan, India, and China, with anticipated expiration between 2032 to 2041, without considering
patent term adjustments or patent term extensions. The below table summarizes the seven patent families that have been issued to-date for
our subsidiary companies:

    Company
Assignee
     
    Family
     
    Status
     
    Type
     
    Granted
Regions
     
    Expiration
Year
  
    Vaximm

    Manufacturing (1)
    WO 2013/091898, Method for Producing High Yield Attenuated Salmonella
    Strains
     
    Owned
     
    Manufacturing
     
    AU, CA, CN, EP,